Biotech drug Simponi approved for arthritis in Canada

04/13/2009 | Reuters

Canadian drug regulators approved biologic drug Simponi to treat moderate to severe rheumatoid arthritis and active psoriatic arthritis. Simponi, a product of Johnson & Johnson and Schering-Plough, is awaiting regulatory clearance in the U.S. and Europe.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC